Gastrointestinal Cancer Committee

Purpose

The purpose of the NRG Gastrointestinal (GI) Cancer Committee is to reduce the burden of GI malignancies in patients. The GI Cancer Committee focuses on testing new hypothesis through clinical trials aimed to improve patient outcomes with GI malignancies. Additionally, the committee focuses on establishing new standard of care that can be applied to all patients.

The goals of this committee include establishing innovative clinical care through evidence-based clinical trials, engaging patients and caregivers in trials and trial development, supporting career development of early career investigators, educating oncology providers on new technologies and techniques, and facilitating team science and multidisciplinary care. This group meets at the NRG Semiannual Meetings, monthly or bi-monthly within Working Groups, and ad-hoc as necessary.

Gastrointestinal Cancer Committee Leadership

Colorectal Chair

Thomas George, MD

Colorectal Vice Chair

Scott Kopetz, MD, PhD, FACP

Non-Colorectal Chair

Theodore Hong, MD

Non-Colorectal Vice Chair

David Ilson, MD, PhD
Working Groups

Pancreas GI Subsite Working Group

Chair

Nina Sanford

Hepatobiliary GI Subsite Working Group

Chair

Laura Dawson

Esophagogastric GI Subsite Working Group

Chair

David Ilson

Neuroendocrine Tumor Working Group

Chair

Heloisa Soares

Anal GI Subsite Working Group

Chair

Jennifer Dorth

Colon GI Subsite Working Group

Chair

Christina Wu

Rectal GI Subsite Working Group

Chair

Kathryn Hitchcock

Core Committee Members

Colorectal Cancer Core Committee

  • Gerard Abood
  • Ghassan Abou-Alfa
  • Olatunji Alese
  • Naba Ali
  • Manik Amin
  • Christopher Anker
  • Shahed N. Badiyan
  • Michael Bassetti
  • Rimini Breakstone
  • Gary Buchshacher
  • Michael Buckstein
  • Cameron M. Callaghan
  • Tobias R.Chapman
  • Jason Cheng
  • Amit K. Chowdhry
  • Steven Cohen
  • Madison L. Conces
  • Michael Cusnir
  • Prajnan Das
  • Arvind Dasari
  • Gemma Davies
  • Laura Dawson
  • Jennifer Dorth
  • Kevin Du
  • Jesus Fabregas
  • Vaia Florou
  • Erin Fukaya
  • Thomas George
  • David S. Goldberg
  • Jun Gong
  • Karyn Goodman
  • Garrett Green
  • Michael Haddock
  • Daniel Haldar
  • William Hall
  • Christopher Hallemeier
  • Jared H. Hara
  • Kathryn Hitchcock
  • Theodore Hong
  • David Horowitz
  • David Ilson
  • Atif Iqbal
  • Alison Ivey
  • Salma Jabbour
  • Einsley-Marie Janowski
  • Krishnan Jethwa
  • Andrea Johnston
  • Lisa Kachnic
  • Jordan Kharofa
  • Aoife Kilcoyne
  • George P. Kim
  • Hyun Kim
  • Samuel Klempner
  • Scott Kopetz
  • Geoffrey Ku
  • Sangjune Lee
  • Caio Rocha Lima
  • Jolinta Lin
  • Yan Lin
  • Diane C. Ling
  • Jonathan M. Loree
  • Kimberly Mak
  • Harvey Mamon
  • Khalid Matin
  • Malcolm Mattes
  • Eric Miller
  • Timur Mitin
  • Juan Pablo Moreno
  • Van Morris
  • Qadan Motaz
  • Boris Naraev
  • Neil Newman
  • Matthew Ng
  • Romaine Charles Nichols
  • Manisha Palta
  • Parag Parikh
  • William Parker
  • Pretesh Patel
  • Sonal Paul
  • Brian Ramnaraign
  • Marsha Reyngold
  • Hannah J. Roberts
  • Sherise Rogers
  • Yesenia Rojas-Khalil
  • Paul Romesser
  • Soumon Rudra
  • Marcia Russell
  • Jeff Ryckman
  • Anwaar Saeed
  • Howard Safran
  • Mohamed Salem
  • Joel Saltzman
  • Nina Sanford
  • Steven Seyedin
  • Zain Siddiqui
  • Heloisa Soares
  • Atsuo Takashima
  • Tarita Thomas
  • Richard Tuli
  • Noam VanderWalde
  • Raymond C. Wadlow
  • Terrence Williams
  • Jennifer Wo
  • Adam Wolfe
  • Christina Wu
  • Evan Wuthrick
  • Greg Yothers
  • Janie Y. Zhang

Non-Colorectal Cancer Core Committee

  • Matthew Abrams
  • Olatunji Alese
  • Naba Ali
  • Christopher Anker
  • Mekhail Anwar
  • Shahed N. Badiyan
  • Michael Bassetti
  • Bruno Bockorny
  • Gehan Botrus
  • Rimini Breakstone
  • Tobias R. Chapman
  • Amit K. Chowdhry
  • Michael Chuong
  • Steven Cohen
  • Prajnan Das
  • Arvind Dasari
  • Gemma Davies
  • Laura Dawson
  • Jennifer Dorth
  • Mary Feng
  • Erin Fukaya
  • Thomas George
  • David S Goldberg
  • Jun Gong
  • Karyn Goodman
  • Garrett Green
  • Michael Haddock
  • Daniel Haldar
  • William Hall
  • Christopher Hallemeier
  • Jared H. Hara
  • Lauren Elizabeth Henke
  • Joseph Herman
  • Kathryn Hitchcock
  • Theodore Hong
  • David P. Horowitz
  • Jasmine Huynh
  • David Ilson
  • Atif Iqbal
  • Salma Jabbour
  • Einsley-Marie Janowski
  • Krishnan Jethwa
  • Andrea Johnston
  • Lisa Kachnic
  • Jordan Kharofa
  • Aoife Kilcoyne
  • George P. Kim
  • Hyun Kim
  • Emily Kinssey
  • Samuel Klempner
  • Eugene Koay
  • Sunil Krishnan
  • Geoffrey Ku
  • Sangjune Lee
  • Caio Rocha Lima
  • Jolinta Lin
  • Jonathan M. Loree
  • Amit Mahipal
  • Kimberly Mak
  • Harvey Mamon
  • Khalid Matin
  • Eric Miller
  • Timur Mitin
  • Qadan Motaz
  • Boris Naraev
  • Ibrahim Nassour
  • Neil Newman
  • Matthew Ng
  • Romaine Charles Nichols
  • Ryan Nipp
  • Russell Palm
  • Manisha Palta
  • Parag Parikh
  • William Parker
  • Pretesh Patel
  • Sonal Paul
  • Brian Ramnaraign
  • Avani Rao
  • Marsha Reyngold
  • Hannah J. Roberts
  • Sherise Rogers
  • Paul Romesser
  • Soumon Rudra
  • Jeff Ryckman
  • Anwaar Saeed
  • Howard Safran
  • Ilyas Sahin
  • Mohamed Salem
  • Joel Saltzman
  • Nina Sanford
  • Steven Seyedin
  • Farzan Siddiqui
  • Austin J. Sim
  • Heloisa Soares
  • Atsuo Takashima
  • Leila Tchelebi
  • Tarita Thomas
  • Richard Tuli
  • Noam VanderWalde
  • Raymond C Wadlow
  • Terence Williams
  • Kathryn Winter
  • Jennifer Wo
  • Adam Wolfe
  • Christina Wu
  • Evan Wuthrick
  • Zhen Zhang
Reset all column filters
Study Title Status Phase Disease Category Disease Site
NRG-GI001

Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma

 Closed to Accrual III Gastrointestinal [GI] Liver
NRG-GI002

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

 Terminated II Gastrointestinal [GI] Anal Canal
NRG-GI003

A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma

 Open to Accrual III Gastrointestinal [GI] Liver
NRG-GI004/SWOG-S1610

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-high (MSI-H) Metastatic Colorectal Cancer

 Closed to Accrual III Gastrointestinal [GI] Colorectal
NRG-GI005

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

 Closed to Accrual II/III Gastrointestinal [GI] Colorectal
NRG-GI006

Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer

 Open to Accrual III Gastrointestinal [GI] Esophageal
NRG-GI007

Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery

 Closed to Accrual & Treatment I Gastrointestinal [GI] Esophageal
NRG-GI008

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)

 Open to Accrual II/III Gastrointestinal [GI] Colorectal
RTOG-0436

A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery

 Terminated III Gastrointestinal [GI] Esophageal
RTOG-0848

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

 Complete III Gastrointestinal [GI] Pancreas
RTOG-1010

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

 Terminated III Gastrointestinal [GI] Esophageal
RTOG-1112

Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

 Terminated III Gastrointestinal [GI] Liver

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.